No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial - Concepedia

Concepedia

Publication | Open Access

No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial

DOI Full Paper Access

12

Citations

17

References

2013

Year

Denis Chopera, Jaclyn K. Mann, Philip Mwimanzi, Saleha Omarjee, Xiaomei T. Kuang, Nonkululeko Ndabambi, Sarah Goodier, Eric S. Martin, Vivek Naranbhai, Salim S. Abdool Karim,

Abstract

Results indicate that the partial protective effects of 1% tenofovir gel use in the CAPRISA 004 trial were not offset by selection of transmitted/early HIV-1 variants with enhanced Gag-Protease or Nef fitness.

References

	Year	Citations

Page 1